Posts

BMS CEO Boerner Says No Compulsion to Chase Deals Despite Quiet M&A Year

on

BMS expands AI footprint with Nvidia, aiming for most powerful AI factory in life sciences

on

Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Use AI and Real‑World Data to Improve Clinical Trial Success

on

Beeline Biotech Launches with $300M Funding and Bristol Myers Squibb-Derived Pipeline

on

Bristol Myers Squibb Partners with Faro to Scale AI in Clinical Trial Protocols

on

Biopharma Bites: FDA Approves High-Dose Spinraza for SMA, J&J's $500M Autoimmune Deal, and Updates from BMS and Boehringer

on

JPM26: BMS Highlights Early-Stage Bets and Pipeline Progress Amid Late-Stage Pharma Focus

on

Harbour BioMed inks $90M upfront, $1B+ antibody alliance with Bristol Myers Squibb

on

FDA Crackdown on Pharma TV Ads Targets Pfizer, Novartis, BMS, Lilly & Others

on

BioNTech and BMS Announce First Global Data for PD-L1xVEGF Bispecific in Small Cell Lung Cancer, Set Phase 3 Dose

on

Over 500 BMS jobs axed in latest round of NJ cuts

on

: BMS' Opdivo plus Yervoy snags FDA nod as first-line treatment for certain colorectal cancer patients

on

BMS snaps up Abecma partner 2seventy bio in $286M all-cash deal

on